National Comprehensive Cancer Network



About NCCN

Central Nervous System Cancers Panel - Disclosures as of 10/17/2012

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Mario Ammirati, MD, MBA

None

None

None

None

3/29/2012

Philip J. Bierman, MD

Otsuka Pharmaceuticals;
Seattle Genetics

None

None

None

5/1/2013

Henry Brem, MD

None

None

None

None

9/27/2012

Nicholas Butowski, MD

None

None

None

None

8/9/2012

Marc C. Chamberlain, MD

NCCN Funded Bendamustine trial for Recurrent High-Grade Gliomas

PharmacoKinesis Advisory Board

None

None

8/9/2012

Lisa M. DeAngelis, MD

None

None

None

None

8/20/2012

Robert A. Fenstermaker, MD

None

None

None

None

8/9/2012

Allan Friedman, MD

None

None

None

None

9/26/2012

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Mark R. Gilbert, MD

RTOG Trial

Abbott Laboratories;
Genentech, Inc.;
Merck & Co., Inc.;
Schering-Plough Corporation

None

None

8/9/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Deneen Hesser, MSHSA, RN, OCN

None

None

None

None

9/27/2012

Maria Ho, PhD

None

None

None

None

8/3/2012

Matthias Holdhoff, MD, PhD

None

None

None

None

11/7/2012

Larry Junck, MD

None

None

None

None

3/14/2013

Ronald Lawson, MD, FACP

None

None

None

None

3/29/2013

Jay S. Loeffler, MD

None

None

None

None

7/16/2012

Moshe H. Maor, MD

None

None

None

None

8/24/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Nicole McMillian, MS

None

None

None

None

3/27/2013

Paul L. Moots, MD

ECOG;
EMD Sereno

None

None

None

10/9/2012

Tara Morrison, MD, FRCPC

None

Merck & Co., Inc.

None

None

10/1/2012

Maciej M. Mrugala, MD, PhD, MPH

None

Enzon Pharmaceuticals;
Schering-Plough Corporation

None

None

11/24/2009

Louis Burt Nabors, MD

AstraZeneca Pharmaceuticals LP;
Boehringer Ingelheim GmbH;
Eli Lilly and Company;
Genentech, Inc.;
GlaxoSmithKline;
ImClone Systems Incorporated;
Merck KGaA;
Transmolecular

Merck KGaA

None

None

3/3/2013

Herbert B. Newton, MD

None

Eisai Inc.;
Genentech, Inc.;
Merck & Co., Inc.

None

None

8/16/2012

Jana Portnow, MD

None

None

None

None

11/28/2012

Jeffrey J. Raizer, MD

Eli Lilly and Company;
Genentech, Inc.;
MedImmune Inc.;
Millennium Pharmaceuticals, Inc.;
Novartis Pharmaceuticals Corporation;
Arno;
Celldex;
Diffusion;
Geron;
Myriad

Enzon Pharmaceuticals;
Genentech, Inc.;
Merck & Co., Inc.;
Novartis Pharmaceuticals Corporation

None

None

10/3/2012

Lawrence Recht, MD

Genentech, Inc.;
Celtic Pharmaceuticals

Genentech, Inc.

None

None

2/27/2013

Dennis C. Shrieve, MD, PhD

None

None

None

None

2/26/2013

Allen K. Sills, MD

None

Merck & Co., Inc.

None

None

10/5/2011

Nam Tran, MD, PhD

None

None

None

None

10/8/2012

David Tran, MD, PhD

None

None

None

None

9/26/2012

Frank D. Vrionis, MD, MPH, PhD

Globus;
Synthes

Florida Board of Medicine;
Southeastern Brain Tumor Association

None

Orthofix

11/13/2012

Patrick Yung Wen, MD

None

Genentech, Inc.

None

None

10/24/2011

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved